Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study
ObjectivesTo compare the efficacy and safety of letermovir and ganciclovir for cytomegalovirus (CMV) prophylaxis in adolescent patients (aged 14-17 years) undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT).MethodsThis observational and single-center study collected data from Fe...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1558637/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849330918288785408 |
|---|---|
| author | Ziwei Xu Xuan Lu Huafang Wang |
| author_facet | Ziwei Xu Xuan Lu Huafang Wang |
| author_sort | Ziwei Xu |
| collection | DOAJ |
| description | ObjectivesTo compare the efficacy and safety of letermovir and ganciclovir for cytomegalovirus (CMV) prophylaxis in adolescent patients (aged 14-17 years) undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT).MethodsThis observational and single-center study collected data from February 2023 and April 2024.ResultsThe cumulative incidence of CMV DNAemia following HSCT was 44.4% in the letermovir group (n=20) and 66.3% in the control group (n=32) receiving ganciclovir. Notably, the cumulative incidence of clinically significant CMV infection (csCMVi) was significantly reduced in the letermovir group compared with control patients (11.0% vs 41.3%, p=0.021). Among patients diagnosed with grades II-IV acute graft-versus-host disease (aGVHD), a significantly lower proportion of individuals in the letermovir group presented CMV DNAemia than in the control group (20.0% vs 73.3%, p=0.013). The common adverse events observed in the letermovir group were aGVHD (60.0%), diarrhea (25.0%), and nausea (15.0%). Leukopenia was reported in only one patient, and did not necessitate an adjustment of letermovir dosage.ConclusionsIn this single-center real-world study, letermovir exhibited a favourable efficacy and safety profile for CMV prophylaxis in adolescent patients undergoing HSCT. However, further prospective multi-center studies are warranted to validate our conclusion in adolescent patients. |
| format | Article |
| id | doaj-art-f070a9b3d08049b5b0553f28a96f2fe8 |
| institution | Kabale University |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-f070a9b3d08049b5b0553f28a96f2fe82025-08-20T03:46:47ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-06-011510.3389/fcimb.2025.15586371558637Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational studyZiwei XuXuan LuHuafang WangObjectivesTo compare the efficacy and safety of letermovir and ganciclovir for cytomegalovirus (CMV) prophylaxis in adolescent patients (aged 14-17 years) undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT).MethodsThis observational and single-center study collected data from February 2023 and April 2024.ResultsThe cumulative incidence of CMV DNAemia following HSCT was 44.4% in the letermovir group (n=20) and 66.3% in the control group (n=32) receiving ganciclovir. Notably, the cumulative incidence of clinically significant CMV infection (csCMVi) was significantly reduced in the letermovir group compared with control patients (11.0% vs 41.3%, p=0.021). Among patients diagnosed with grades II-IV acute graft-versus-host disease (aGVHD), a significantly lower proportion of individuals in the letermovir group presented CMV DNAemia than in the control group (20.0% vs 73.3%, p=0.013). The common adverse events observed in the letermovir group were aGVHD (60.0%), diarrhea (25.0%), and nausea (15.0%). Leukopenia was reported in only one patient, and did not necessitate an adjustment of letermovir dosage.ConclusionsIn this single-center real-world study, letermovir exhibited a favourable efficacy and safety profile for CMV prophylaxis in adolescent patients undergoing HSCT. However, further prospective multi-center studies are warranted to validate our conclusion in adolescent patients.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1558637/fulladolescentscytomegalovirusletermovirganciclovirHSCThematopoietic stem cell transplant |
| spellingShingle | Ziwei Xu Xuan Lu Huafang Wang Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study Frontiers in Cellular and Infection Microbiology adolescents cytomegalovirus letermovir ganciclovir HSCT hematopoietic stem cell transplant |
| title | Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study |
| title_full | Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study |
| title_fullStr | Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study |
| title_full_unstemmed | Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study |
| title_short | Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study |
| title_sort | real world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation a single center observational study |
| topic | adolescents cytomegalovirus letermovir ganciclovir HSCT hematopoietic stem cell transplant |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1558637/full |
| work_keys_str_mv | AT ziweixu realworldefficacyandsafetyofletermovirversusganciclovirprophylaxisinadolescentpatientsundergoingallogenichematopoieticstemcelltransplantationasinglecenterobservationalstudy AT xuanlu realworldefficacyandsafetyofletermovirversusganciclovirprophylaxisinadolescentpatientsundergoingallogenichematopoieticstemcelltransplantationasinglecenterobservationalstudy AT huafangwang realworldefficacyandsafetyofletermovirversusganciclovirprophylaxisinadolescentpatientsundergoingallogenichematopoieticstemcelltransplantationasinglecenterobservationalstudy |